Latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma – Pipeline Review, H1 2018, provides an overview of the Neuroblastoma pipeline landscape.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neuroblastoma , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are:- 3, 30, 15, 3, 44, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 14 and 3 molecules, respectively.

Neuroblastoma pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Companies Mentioned in Neuroblastoma are: Ability Pharmaceuticals SL, Actuate Therapeutics Inc, Alissa Pharma, Ampio Pharmaceuticals Inc, APEIRON Biologics AG, AstraZeneca Plc, Autolus Ltd, Bayer AG, Bellicum Pharmaceuticals Inc, Bexion Pharmaceuticals LLC, Bio-Cancer Treatment International Ltd, BioLineRx Ltd, Biotec Pharmacon ASA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Cancer Prevention Pharmaceuticals Inc, Cancer Therapeutics CRC Pty Ltd, Cebiotex SL, Celgene Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Cielo Therapeutics Inc, Cleveland BioLabs Inc, CorMedix Inc, Curis Inc, Cyclacel Pharmaceuticals Inc, DEKK-TEC Inc, EnGeneIC Ltd, Epizyme Inc, Errant Gene Therapeutics LLC, F. Hoffmann-La Roche Ltd, GC Pharma, GlaxoSmithKline Plc, ID Pharma Co Ltd, Ignyta Inc, Ipsen SA, Juno Therapeutics Inc, Kazia Therapeutics Ltd, Loxo Oncology Inc, MabVax Therapeutics Holdings Inc, MacroGenics Inc, MediaPharma SRL, Merck & Co Inc, Morphogenesis Inc, Novartis AG, OGD2 Pharma SAS, Pfizer Inc, Phylogica Ltd, Progenics Pharmaceuticals Inc, Recombio SL, Ribomic Inc, Sapience Therapeutics Inc, Sareum Holdings Plc, Sierra Oncology Inc, Sorrento Therapeutics Inc, Syros Pharmaceuticals Inc, TheraBiologics Inc, Trellis Bioscience Inc, ZIOPHARM Oncology Inc”

Request for a Sample Copy of this Research Report at:


  1. The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma.
    2. The pipeline guide reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
    3. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    4. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    5. The pipeline guide reviews key companies involved in Neuroblastoma therapeutics and enlists all their major and minor projects.
    6. The pipeline guide evaluates Neuroblastoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    7. The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    8. The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma

Browse full Report at:

Reasons to buy this Report:

1. procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
2. Find and recognize significant and varied types of therapeutics under development for Neuroblastoma.
Classify potential new clients or partners in the target demographic.
3. Develop tactical initiatives by understanding the focus areas of leading companies.
4. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
5. Formulate corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics.
6. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
7. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Important Points Covered In Table of Content are:

Therapeutics Assessment, Assessment by Target, Assessment by Mechanism of Action, Assessment by Route of Administration, Assessment by Molecule Type, Pipeline Overview, Pipeline by Companies, Pipeline by Universities/Institutes, Products under Development by Companies, Products under Development by Universities/Institutes.